FR08C0026I1 - - Google Patents
Info
- Publication number
- FR08C0026I1 FR08C0026I1 FR08C0026C FR08C0026I1 FR 08C0026 I1 FR08C0026 I1 FR 08C0026I1 FR 08C0026 C FR08C0026 C FR 08C0026C FR 08C0026 I1 FR08C0026 I1 FR 08C0026I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33956801P | 2001-10-26 | 2001-10-26 | |
US36219102P | 2002-03-06 | 2002-03-06 | |
PCT/GB2002/004753 WO2003035077A1 (en) | 2001-10-26 | 2002-10-21 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
Publications (2)
Publication Number | Publication Date |
---|---|
FR08C0026I1 true FR08C0026I1 (de) | 2008-07-18 |
FR08C0026I2 FR08C0026I2 (fr) | 2010-01-22 |
Family
ID=26991691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR08C0026C Active FR08C0026I2 (fr) | 2001-10-26 | 2008-06-17 | Inhibiteurs de l'integrase du vih a base d'hydroxypyrimidinone carboxamide n-substitue |
Country Status (35)
Country | Link |
---|---|
US (5) | US7169780B2 (de) |
EP (1) | EP1441735B1 (de) |
JP (1) | JP3927175B2 (de) |
KR (1) | KR100862879B1 (de) |
CN (3) | CN102219750B (de) |
AT (1) | ATE318140T1 (de) |
BR (1) | BRPI0213522C1 (de) |
CA (1) | CA2463976C (de) |
CO (1) | CO5580777A2 (de) |
CY (1) | CY2008008I1 (de) |
DE (3) | DE122008000016I1 (de) |
DK (1) | DK1441735T3 (de) |
EA (1) | EA007060B1 (de) |
ES (1) | ES2258668T3 (de) |
FR (1) | FR08C0026I2 (de) |
GE (1) | GEP20063848B (de) |
HK (1) | HK1085665A1 (de) |
HR (1) | HRP20040373B1 (de) |
HU (2) | HU230248B1 (de) |
IL (2) | IL161337A0 (de) |
IS (1) | IS2436B (de) |
LT (1) | LTC1441735I2 (de) |
LU (1) | LU91428I2 (de) |
ME (1) | ME00427B (de) |
MX (1) | MXPA04003932A (de) |
NL (1) | NL300340I2 (de) |
NO (3) | NO325206B1 (de) |
NZ (1) | NZ533057A (de) |
PL (1) | PL212914B1 (de) |
PT (1) | PT1441735E (de) |
RS (1) | RS51542B (de) |
SI (1) | SI1441735T1 (de) |
UA (1) | UA77454C2 (de) |
WO (1) | WO2003035077A1 (de) |
ZA (1) | ZA200402796B (de) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1326611B1 (de) | 2000-10-12 | 2007-06-13 | Merck & Co., Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
NZ525088A (en) | 2000-10-12 | 2004-11-26 | Merck & Co Inc | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors |
JP2004517860A (ja) | 2000-10-12 | 2004-06-17 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
EP2181985B1 (de) * | 2001-08-10 | 2011-10-26 | Shionogi & Co., Ltd. | Antivirales Mittel |
AR036256A1 (es) | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
WO2003035076A1 (en) * | 2001-10-26 | 2003-05-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
CN102219750B (zh) * | 2001-10-26 | 2013-05-29 | P.安杰莱蒂分子生物学研究所 | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 |
ATE409187T1 (de) | 2002-03-15 | 2008-10-15 | Merck & Co Inc | N-(substituierte benzyl)-8-hydroxy-1,6- naphthyridin-7- carbonsäureamide als hiv- integrase-hemmer |
CN100491358C (zh) * | 2002-05-09 | 2009-05-27 | 赛特凯恩蒂克公司 | 嘧啶酮类化合物、组合物及方法 |
WO2003099211A2 (en) * | 2002-05-23 | 2003-12-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
JP2006506352A (ja) | 2002-09-11 | 2006-02-23 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−1,6−ジオン化合物 |
EP1539714B1 (de) | 2002-09-11 | 2008-08-13 | Merck & Co., Inc. | 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen |
WO2004058756A1 (en) * | 2002-12-27 | 2004-07-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors |
US7135467B2 (en) * | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
JP2007509149A (ja) | 2003-10-20 | 2007-04-12 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なヒドロキシピリドピロロピラジンジオン化合物 |
US20050090668A1 (en) * | 2003-10-28 | 2005-04-28 | Dreher Spencer D. | Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds |
AR046938A1 (es) * | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
CA2547209A1 (en) | 2003-12-19 | 2005-07-07 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
TW200526635A (en) * | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
BRPI0506786A (pt) * | 2004-01-12 | 2007-05-22 | Gilead Sciences Inc | compostos antivirais de fosfonato de pirimidila e processos de uso |
WO2005087768A1 (en) | 2004-03-09 | 2005-09-22 | Merck & Co., Inc. | Hiv integrase inhibitors |
CN1930161A (zh) | 2004-03-09 | 2007-03-14 | P·安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
WO2005092099A1 (en) | 2004-03-09 | 2005-10-06 | Merck & Co., Inc. | Hiv integrase inhibitors |
JP2007528396A (ja) | 2004-03-09 | 2007-10-11 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬 |
WO2005110414A2 (en) * | 2004-05-07 | 2005-11-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
US7115601B2 (en) * | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
US7173022B2 (en) * | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
CN101146540A (zh) | 2004-06-09 | 2008-03-19 | 默克公司 | Hiv整合酶抑制剂 |
EP1824957A4 (de) * | 2004-12-03 | 2011-02-09 | Merck Sharp & Dohme | Verwendung von atazanavir zur verbesserung der pharmakokinetik von durch ugt1a1 umgewandelte arzneimittel |
WO2006060711A2 (en) * | 2004-12-03 | 2006-06-08 | Merck & Co., Inc. | Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition |
CA2588465C (en) | 2004-12-03 | 2013-10-01 | Merck & Co., Inc. | Pharmaceutical composition containing an anti-nucleating agent |
UA87884C2 (uk) * | 2004-12-03 | 2009-08-25 | Мерк Энд Ко., Инк. | Безводна кристалічна калієва сіль інгібітора віл-інтегрази |
CN101146811B (zh) * | 2005-03-31 | 2012-01-11 | P.安杰莱蒂分子生物学研究所 | Hiv整合酶抑制剂 |
PT1874117E (pt) | 2005-04-28 | 2013-10-17 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse |
CA2607151C (en) | 2005-05-10 | 2012-06-19 | Merck & Co., Inc. | Hiv integrase inhibitors |
AU2006272521A1 (en) * | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of HIV |
AU2006299042B8 (en) * | 2005-10-04 | 2011-09-15 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | HIV integrase inhibitors |
WO2007050510A2 (en) * | 2005-10-27 | 2007-05-03 | Merck & Co., Inc. | Hiv integrase inhibitors |
US20070129379A1 (en) * | 2005-12-01 | 2007-06-07 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
WO2007087188A2 (en) * | 2006-01-20 | 2007-08-02 | Merck & Co., Inc. | Taste-masked tablets and granules |
CA2657287A1 (en) * | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
JP2009543865A (ja) | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション, インコーポレーテッド | ピリジノンジケト酸:併用療法におけるhiv複製の阻害剤 |
CA2665538A1 (en) * | 2006-10-18 | 2008-04-24 | Merck & Co., Inc. | Hiv integrase inhibitors |
CN101206209B (zh) * | 2006-12-19 | 2011-08-10 | 北京德众万全药物技术开发有限公司 | 一种用hplc法分析西多福韦原料及其制剂的方法 |
US7763630B2 (en) * | 2007-06-06 | 2010-07-27 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
MX2009013462A (es) * | 2007-06-22 | 2010-01-15 | Bristol Myers Squibb Co | Composiciones comprimidas que contienen atazanavir. |
US7687509B2 (en) * | 2007-07-09 | 2010-03-30 | Concert Pharmaceuticals Inc. | Pyrimidinecarboxamide derivatives |
US20110015158A1 (en) | 2007-12-11 | 2011-01-20 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
RU2495878C2 (ru) | 2007-12-21 | 2013-10-20 | Ф.Хоффманн-Ля Рош Аг | Гетероциклические антивирусные соединения |
WO2009088729A1 (en) * | 2008-01-08 | 2009-07-16 | Merck & Co., Inc. | Process for preparing n-substituted hydroxypyrimidinone carboxamides |
WO2010000030A1 (en) * | 2008-07-02 | 2010-01-07 | Avexa Limited | Thiazopyrimidinones and uses thereof |
EA201170537A1 (ru) * | 2008-10-06 | 2011-12-30 | Мерк Шарп Энд Домэ Корп. | Ингибиторы вич-интегразы |
US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
EP2438062B1 (de) | 2009-06-02 | 2015-07-29 | Hetero Research Foundation | Verfahren zur herstellung von amorphem raltegravir-kalium |
CN102471316B (zh) * | 2009-07-06 | 2013-12-11 | 先正达参股股份有限公司 | 杀虫化合物 |
WO2011024192A2 (en) | 2009-07-27 | 2011-03-03 | Matrix Laboratories Ltd | Novel polymorphs of raltegravir |
US8383639B2 (en) | 2009-10-15 | 2013-02-26 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
MY162494A (en) | 2009-10-26 | 2017-06-15 | Merck Sharp & Dohme | Solid pharmaceutical compositions containing an integrase inhibitor |
DE102009056636A1 (de) | 2009-12-02 | 2011-06-09 | Ratiopharm Gmbh | Raltegravir-Polymorphe |
US8283366B2 (en) | 2010-01-22 | 2012-10-09 | Ambrilia Biopharma, Inc. | Derivatives of pyridoxine for inhibiting HIV integrase |
US9260413B2 (en) | 2010-03-04 | 2016-02-16 | Merck Sharp & Dohme Corp. | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders |
JP5995728B2 (ja) | 2010-03-04 | 2016-09-21 | メルク・シャープ・エンド・ドーム・コーポレイション | カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用 |
JP5937971B2 (ja) * | 2010-03-04 | 2016-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | カテコールo−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用 |
RU2563634C2 (ru) | 2010-03-04 | 2015-09-20 | Мерк Шарп Энд Домэ Корп. | Ингибиторы катехол-о-метилтрансферазы и их применение для лечения психотических расстройств |
CA2999435A1 (en) * | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
RU2012146517A (ru) | 2010-04-01 | 2014-05-10 | Тева Фармасьютикал Индастриз Лтд. | Соли ральтегравира и их кристаллические формы |
WO2011127244A2 (en) | 2010-04-09 | 2011-10-13 | Bristol-Myers Squibb Company | ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT |
EP2575465A4 (de) | 2010-05-25 | 2013-11-20 | Hetero Research Foundation | Raltegravir-salze |
US9107922B2 (en) | 2010-07-16 | 2015-08-18 | Concert Pharmaceuticals, Inc. | Pyrimidinecarboxamide derivatives |
CN101914067B (zh) * | 2010-08-26 | 2012-07-11 | 陈岱岭 | N-甲基嘧啶酮的合成方法 |
WO2012103105A1 (en) | 2011-01-24 | 2012-08-02 | Assia Chemical Industries Ltd. | Processes for preparing raltegravir and intermediates in the processes |
AU2012241050B2 (en) | 2011-04-06 | 2016-05-19 | Lupin Limited | Novel salts of raltegravir |
US9968607B2 (en) | 2011-04-25 | 2018-05-15 | Hetero Research Foundation | Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof |
EP2522665A1 (de) | 2011-05-03 | 2012-11-14 | Sandoz Ag | Kristallinnatriumsalz eines HIV-Integrasehemmers |
EP2529741B1 (de) | 2011-06-01 | 2014-02-12 | Ratiopharm GmbH | Zusammensetzung und Tablette beinhaltend Raltegravir |
CN103130788B (zh) * | 2011-11-24 | 2015-09-02 | 南开大学 | 嘧啶酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
CN103130787B (zh) * | 2011-11-24 | 2015-06-10 | 南开大学 | 嘧啶酮酰胺类化合物及其制备方法、抗hiv活性和抗tmv活性 |
CN104185420B (zh) | 2011-11-30 | 2017-06-09 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
WO2013098854A2 (en) * | 2011-12-26 | 2013-07-04 | Emcure Pharmaceuticals Limited | Synthesis of raltegravir |
BR112014018247A8 (pt) | 2012-01-25 | 2017-07-11 | Lupin Ltd | Pré-mistura de potássio de raltegravir amorfa e estável; processo; formulação farmacêutica; e método |
EP2875024A4 (de) * | 2012-07-20 | 2015-12-23 | Merck Sharp & Dohme | Hiv-behandlung mit amidosubstituierten pyrimidinonderivaten |
BR112015002516A2 (pt) * | 2012-08-06 | 2017-07-04 | European Molecular Biology Laboratory | derivados de ácido carbônico di-hidroxipirimidina e seu uso no tratamento, melhora ou prevenção de doença viral. |
CN102911124B (zh) * | 2012-10-25 | 2015-11-25 | 山东大学 | 羟基嘧啶酮类化合物及其制备方法与应用 |
US9227990B2 (en) | 2012-10-29 | 2016-01-05 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
EP2931730B1 (de) | 2012-12-17 | 2019-08-07 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazinderivate als hiv-integrase-hemmer |
PL2822954T3 (pl) | 2012-12-21 | 2016-09-30 | Policykliczne związki karbamoilopirydonu i ich farmaceutyczne zastosowanie | |
US9493479B2 (en) | 2013-04-16 | 2016-11-15 | Merck Sharp & Dohme Corp. | Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors |
RS56701B1 (sr) | 2013-05-17 | 2018-03-30 | Merck Sharp & Dohme | Fuzionisana triciklična heterociklična jedinjenja kao inhibitori hiv integraze |
WO2014200880A1 (en) | 2013-06-13 | 2014-12-18 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
SI3252058T1 (sl) | 2013-07-12 | 2021-03-31 | Gilead Sciences, Inc. | Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje okužb s HIV |
NO2865735T3 (de) | 2013-07-12 | 2018-07-21 | ||
CA2924829C (en) | 2013-09-27 | 2019-10-29 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
WO2015096651A1 (en) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
EP3102565B1 (de) * | 2014-02-03 | 2019-01-02 | Mylan Laboratories Ltd. | Verfahren zur herstellung von raltegravir-intermediaten |
CA2942239C (en) | 2014-03-21 | 2020-09-22 | Mylan Laboratories Ltd. | A premix of crystalline raltegravir potassium salt and a process for the preparation thereof |
TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
NO2717902T3 (de) | 2014-06-20 | 2018-06-23 | ||
US9353093B2 (en) | 2014-10-07 | 2016-05-31 | Allergan, Inc. | Indole-1-carboxamides as kinase inhibitors |
US10259778B2 (en) | 2014-11-10 | 2019-04-16 | Aurobindo Pharma Ltd | Process for the preparation of raltegravir |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
WO2016154081A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
NZ735575A (en) | 2015-04-02 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
WO2016187788A1 (en) | 2015-05-25 | 2016-12-01 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds useful for treating hiv infection |
EP3313852B1 (de) | 2015-06-25 | 2021-01-20 | Merck Sharp & Dohme Corp. | Substituierte bicyclische pyrazolo/imidazolo-verbindungen als pde2-inhibitoren |
WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
WO2017087257A1 (en) | 2015-11-17 | 2017-05-26 | Merck Sharp & Dohme Corp. | Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors |
WO2017106071A1 (en) | 2015-12-15 | 2017-06-22 | Merck Sharp & Dohme Corp. | Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors |
WO2017113288A1 (en) | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
WO2017220208A1 (en) | 2016-06-21 | 2017-12-28 | Pharmathen S.A. | Process for preparing compounds useful as intermediates for the preparation of raltegravir |
EP3512854A1 (de) | 2016-09-15 | 2019-07-24 | Lupin Limited | Verfahren zur herstellung von reinem und stabilem kristallinem raltegravirkalium form 3 |
RU2749043C2 (ru) | 2016-12-02 | 2021-06-03 | Мерк Шарп И Доум Корп. | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
WO2018140368A1 (en) | 2017-01-26 | 2018-08-02 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
SI3710445T1 (sl) | 2017-11-14 | 2022-05-31 | Cambrex Profarmaco Milano S.R.L. | Postopek za pripravo raltegravirja |
AU2020316056A1 (en) * | 2019-07-23 | 2022-02-03 | Constellation Pharmaceuticals, Inc. | Modulators of TREX1 |
US20230073216A1 (en) | 2020-01-23 | 2023-03-09 | Lupin Limited | Pharmaceutical Compositions of Raltegravir |
WO2021165927A1 (en) * | 2020-02-21 | 2021-08-26 | Wockhardt Bio Ag | 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE56503B1 (en) | 1985-03-16 | 1991-08-14 | Wellcome Found | Antiviral nucleosides |
US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
US5637618A (en) | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
DE4029654A1 (de) | 1990-09-19 | 1992-04-02 | Hoechst Ag | 2-phenyl-pyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
US5663169A (en) | 1992-08-07 | 1997-09-02 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
TW287160B (de) | 1992-12-10 | 1996-10-01 | Hoffmann La Roche | |
US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
EP1069111A4 (de) | 1998-03-26 | 2001-06-06 | Shionogi & Co | Indol derivate mit antiviraler aktivität |
US6306891B1 (en) | 1998-06-03 | 2001-10-23 | Merck & Co., Inc. | HIV integrase inhibitors |
CA2333707A1 (en) | 1998-06-03 | 1999-12-09 | Melissa Egbertson | Hiv integrase inhibitors |
AU757409B2 (en) | 1998-06-03 | 2003-02-20 | Merck & Co., Inc. | Hiv integrase inhibitors |
CZ301763B6 (cs) | 1998-08-20 | 2010-06-16 | Toyama Chemical Co., Ltd. | Protivirový prostredek a derivát dusíkatého heterocyklického karboxamidu |
HUP0201472A3 (en) | 1998-12-25 | 2006-03-28 | Shionogi & Co | Aromatic heterocycle compounds having hiv integrase inhibiting activities |
EP1159271B1 (de) * | 1999-03-04 | 2004-08-25 | Korea Research Institute of Chemical Technology | Anivirale 2,4-pyrimidindion-derivate und ein verfahren zu ihrer herstellung |
EP1196384A4 (de) | 1999-06-25 | 2002-10-23 | Merck & Co Inc | 1-(aromatisch oder heteroaromatisch substituierte)-3-(heteroaromatisch substituiert)-1,3-propandione und ihre anwendungen |
JP5230050B2 (ja) * | 2000-05-08 | 2013-07-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Hiv複製阻害剤 |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
EP1326611B1 (de) | 2000-10-12 | 2007-06-13 | Merck & Co., Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
NZ525088A (en) | 2000-10-12 | 2004-11-26 | Merck & Co Inc | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors |
US20050010048A1 (en) | 2000-10-12 | 2005-01-13 | Linghang Zhuang | Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors |
JP2004517860A (ja) | 2000-10-12 | 2004-06-17 | メルク エンド カムパニー インコーポレーテッド | Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
DE60229364D1 (de) | 2001-03-01 | 2008-11-27 | Shionogi & Co | Stickstoffhaltige heteroarylverbindungen mit hiv-integrase inhibierender wirkung |
EP2181985B1 (de) | 2001-08-10 | 2011-10-26 | Shionogi & Co., Ltd. | Antivirales Mittel |
CN102219750B (zh) | 2001-10-26 | 2013-05-29 | P.安杰莱蒂分子生物学研究所 | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 |
WO2003035076A1 (en) | 2001-10-26 | 2003-05-01 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
WO2003047564A1 (fr) | 2001-12-05 | 2003-06-12 | Shionogi & Co., Ltd. | Dérivé ayant une activité d'inhibition de l'intégrase du vih |
AU2003248872A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
ATE443048T1 (de) | 2002-11-20 | 2009-10-15 | Japan Tobacco Inc | 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren |
US7135467B2 (en) | 2003-01-13 | 2006-11-14 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
-
2002
- 2002-10-21 CN CN2011100924805A patent/CN102219750B/zh not_active Expired - Lifetime
- 2002-10-21 JP JP2003537644A patent/JP3927175B2/ja not_active Expired - Lifetime
- 2002-10-21 DE DE200812000016 patent/DE122008000016I1/de active Pending
- 2002-10-21 IL IL16133702A patent/IL161337A0/xx unknown
- 2002-10-21 ES ES02801950T patent/ES2258668T3/es not_active Expired - Lifetime
- 2002-10-21 ME MEP-2008-637A patent/ME00427B/me unknown
- 2002-10-21 DK DK02801950T patent/DK1441735T3/da active
- 2002-10-21 EA EA200400585A patent/EA007060B1/ru active Protection Beyond IP Right Term
- 2002-10-21 DE DE60209381T patent/DE60209381T2/de not_active Expired - Lifetime
- 2002-10-21 SI SI200230296T patent/SI1441735T1/sl unknown
- 2002-10-21 PT PT02801950T patent/PT1441735E/pt unknown
- 2002-10-21 BR BRPI0213522A patent/BRPI0213522C1/pt not_active IP Right Cessation
- 2002-10-21 EP EP02801950A patent/EP1441735B1/de not_active Expired - Lifetime
- 2002-10-21 RS YUP-356/04A patent/RS51542B/sr unknown
- 2002-10-21 AT AT02801950T patent/ATE318140T1/de active
- 2002-10-21 US US10/493,280 patent/US7169780B2/en not_active Expired - Lifetime
- 2002-10-21 MX MXPA04003932A patent/MXPA04003932A/es active IP Right Grant
- 2002-10-21 CN CN028257650A patent/CN1700918B/zh not_active Expired - Lifetime
- 2002-10-21 CA CA002463976A patent/CA2463976C/en not_active Expired - Lifetime
- 2002-10-21 NZ NZ533057A patent/NZ533057A/en not_active IP Right Cessation
- 2002-10-21 CN CN201110092477.3A patent/CN102229605B/zh not_active Expired - Lifetime
- 2002-10-21 DE DE122009000048C patent/DE122009000048I1/de active Pending
- 2002-10-21 HU HU0401740A patent/HU230248B1/hu active Protection Beyond IP Right Term
- 2002-10-21 GE GE5592A patent/GEP20063848B/en unknown
- 2002-10-21 WO PCT/GB2002/004753 patent/WO2003035077A1/en active IP Right Grant
- 2002-10-21 KR KR1020047006234A patent/KR100862879B1/ko active IP Right Grant
- 2002-10-21 UA UA20040503960A patent/UA77454C2/uk unknown
- 2002-10-21 PL PL369223A patent/PL212914B1/pl unknown
-
2004
- 2004-04-07 IS IS7213A patent/IS2436B/is unknown
- 2004-04-09 IL IL161337A patent/IL161337A/en active IP Right Grant
- 2004-04-13 ZA ZA2004/02796A patent/ZA200402796B/en unknown
- 2004-04-21 CO CO04036632A patent/CO5580777A2/es active IP Right Grant
- 2004-04-26 HR HRP20040373AA patent/HRP20040373B1/xx not_active IP Right Cessation
- 2004-05-25 NO NO20042165A patent/NO325206B1/no not_active IP Right Cessation
-
2006
- 2006-05-16 HK HK06105678.2A patent/HK1085665A1/xx not_active IP Right Cessation
- 2006-07-24 US US11/491,815 patent/US7217713B2/en not_active Expired - Lifetime
- 2006-12-19 US US11/641,508 patent/US7435734B2/en not_active Expired - Lifetime
-
2008
- 2008-03-31 NL NL300340C patent/NL300340I2/nl unknown
- 2008-04-08 LU LU91428C patent/LU91428I2/fr unknown
- 2008-04-11 CY CY200800008C patent/CY2008008I1/el unknown
- 2008-04-18 LT LTPA2008007C patent/LTC1441735I2/lt unknown
- 2008-06-06 NO NO2008007C patent/NO2008007I1/no not_active IP Right Cessation
- 2008-06-17 FR FR08C0026C patent/FR08C0026I2/fr active Active
- 2008-06-20 US US12/214,595 patent/US7820660B2/en not_active Expired - Lifetime
-
2010
- 2010-09-17 US US12/884,734 patent/US20110034449A1/en not_active Abandoned
-
2016
- 2016-04-07 HU HUS1600016C patent/HUS1600016I1/hu unknown
-
2020
- 2020-08-10 NO NO2020026C patent/NO2020026I1/no not_active IP Right Cessation